I do not use molecular imaging (e.g., PSMA-PET/CT) for patients with CRPC (including both mCRPC and nmCRPC) except as a screening tool for Pluvicto eligibility for three reasons. Most patients have metastasis already. In one study that used molecular imaging in patients with nmCRPC, they identified...